Nephrogenic Fibrosing Dermopathy: Clinical Trials

10 trials for Nephrogenic Fibrosing Dermopathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 unknown, 1 terminated, 1 withdrawn. 3 Phase 4, 2 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 43Completed 1, Terminated 1, Unknown 1
Phase 22Completed 1, Unknown 1
Phase 32Completed 1, Unknown 1

Follow Nephrogenic Fibrosing Dermopathy: new trials by email Literature Review of Nephrogenic Fibrosing Dermopathy trials Research Report on Nephrogenic Fibrosing Dermopathy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
Gadodiamide, Gadoteric Acid Meglumine Salt - Nephrogenic Fibrosing Dermopathy
Phase 4UnknownThe Central Hospital of Lishui City6002021-03-012021-03-01
Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
Ablavar - Nephrogenic Systemic Fibrosis
CompletedLantheus Medical Imaging22009-10-012014-05-07
Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
Imatinib mesylate (Glivec) - Nephrogenic Systemic Fibrosis
Phase 3CompletedUniversity of Aarhus102009-09-012012-06-05
Primovist / Eovist in Renally Impaired Patients
Gadoxetic acid disodium (Primovist, BAY86-4873) - Contrast Media
Phase 4CompletedBayer3572009-05-012015-07-23
Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis
Nephrogenic Systemic Fibrosis
CompletedMassachusetts General Hospital602009-03-012010-12-15
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Nephrogenic Systemic Fibrosis, Renal Insufficiency
WithdrawnGuerbet2009-02-012017-08-02
Nephrogenic Systemic Fibrosis With Gadollinum
gadollinum - Nephrogenic Systemic Fibrosis, Renal Failure
Phase 2 / Phase 3UnknownImam Khomeini Hospital2002008-07-012012-06-22
Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Imatinib mesylate - Nephrogenic Systemic Fibrosis
Phase 2CompletedMassachusetts General Hospital122007-12-012017-05-19
Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Nephrogenic Systemic Fibrosis, Nephrogenic Fibrosing Dermopathy
CompletedNorthwestern University242007-08-012014-12-04
Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
Plasmapheresis - Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis
Phase 4TerminatedLoma Linda University122002-02-012014-11-21

Narrower conditions

Renal Insufficiency (3)  ·  Kidney Diseases (1)  ·  Kidney Failure, Chronic (1)  ·  Renal Insufficiency, Chronic (1)

Broader conditions

Fibrosis (10)  ·  Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Skin Diseases (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Female Urogenital Diseases (5)  ·  Female Urogenital Diseases and Pregnancy Complications (5)  ·  Male Urogenital Diseases (5)  ·  Urogenital Diseases (5)  ·  Urologic Diseases (5)  ·  Kidney Diseases (4)  ·  Chronic Disease (2)  ·  Disease Attributes (2)  ·  Renal Insufficiency (1)  ·  Renal Insufficiency, Chronic (1)

Interventions

Imatinib Mesylate (2)  ·  Plasmapheresis (1)  ·  gadodiamide (1)  ·  gadolinium ethoxybenzyl DTPA (1)

Sponsors

Massachusetts General Hospital (2)  ·  Bayer (1)  ·  Guerbet (1)  ·  Imam Khomeini Hospital (1)  ·  Lantheus Medical Imaging (1)  ·  Loma Linda University (1)  ·  Northwestern University (1)  ·  The Central Hospital of Lishui City (1)  ·  University of Aarhus (1)

Countries

United States (7)  ·  Australia (1)  ·  Austria (1)  ·  China (1)  ·  Denmark (1)  ·  Germany (1)  ·  Iran (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)  ·  Thailand (1)  ·  United Kingdom (1)

Top investigators

Jonathan Kay, MD (2)  ·  Anne B Olesen, MD,PhD (1)  ·  Anne Laumann, MBChB, MRCP(UK) (1)  ·  Herbert R. Neuman, MD (1)  ·  Mohammad R Khatami, MD (1)  ·  Pedro Baron, MD (1)  ·  Simon P Robinson, PhD (1)

Results publications

PMID 23097320

NIH funding

2008 (1)